[
    {
        "title": "Svensson B, Boonen A, Albertsson K, Heijde Dvd, Keller C, Hafstrom I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis & Rheumatism. 2005;52(11):3360.",
        "paper_uid": "1b777329",
        "reference": "Svensson B, Boonen A, Albertsson K, Heijde Dvd, Keller C, Hafstrom I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis & Rheumatism. 2005;52(11):3360.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Ajeganova S, Svensson B, Hafstrom I. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open. 2014;4(4).",
        "paper_uid": "1a7c95b6",
        "reference": "Ajeganova S, Svensson B, Hafstrom I. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open. 2014;4(4).",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    }
]